Evogene Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
20.1%projected annual EPS growth
Analyst Coverage
1analyst covering
FY EPS (est.)
-$1.70next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 19 Nov 2026 |
| Q4 and Full Year 2026 Earnings Release | 11 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Consolidated Cash, Cash Equivalents, and Short-Term Bank Deposits Quarterly13.1M
Quarterly Revenue Quarterly334K
Quarterly Net Loss Quarterly5.9M
Active Pharmaceutical Collaborations Quarterly400.0%
Watch Items
- ChemPass AI Partnership SigningsTrigger: Fewer than 10 partnerships signed by early 2027Action: Re-evaluate business development strategy and commercial outreach for the computational chemistry platform.
- Cash Runway and Burn RateTrigger: Consolidated cash usage exceeding $3.0 million per quarter without new non-dilutive fundingAction: Implement further cost-reduction measures or execute additional warrant inducement/ATM share sales.
- Preclinical Molecule ProgressTrigger: Failure of designed small molecules to enter preclinical testing by 1H 2027Action: Review computational predictive models and optimize the iterative experimental validation loop.
Research as of 20 Jun 2026